The Chemical Data

National Hospital

GenSight Biologics and 15–20 National Hospital begin first GS010/LUMEVOQ® treatments under France’s AAC program.

The 15-20 National Hospital and GenSight Biologics Announce the First Treatments in the French Named Patient Early Access Program (AAC) for GS010/LUMEVOQ® The 15-20 National Hospital (l’Hôpital national des 15-20) in Paris and GenSight Biologics (Euronext: SIGHT, ISIN: FR0013183985, PEA-PME…

Read MoreGenSight Biologics and 15–20 National Hospital begin first GS010/LUMEVOQ® treatments under France’s AAC program.
Ionis

Ionis Pharmaceuticals: FDA Grants Priority Review for Zilganersen in Alexander disease

Ionis announces zilganersen New Drug Application for Alexander disease (AxD) accepted by FDA for Priority Review Ionis Pharmaceuticals, Inc. announced that the U.S. Food and Drug Administration (FDA) has accepted for Priority Review the New Drug Application (NDA) for zilganersen, an…

Read MoreIonis Pharmaceuticals: FDA Grants Priority Review for Zilganersen in Alexander disease
Biocytogen

Biocytogen Announces Strategic Collaboration with Moonlight Bio to Advance Cell Therapies Using Antibody Binder Library

Biocytogen Announces Strategic Collaboration with Moonlight Bio to Advance Cell Therapies Using Library of Antibody Binders Biocytogen Pharmaceuticals a global biotechnology company that drives the research and development of novel antibody-based drugs with innovative technologies, announced a strategic collaboration with…

Read MoreBiocytogen Announces Strategic Collaboration with Moonlight Bio to Advance Cell Therapies Using Antibody Binder Library
Pfizer

Pfizer and Valneva Report Promising Results as Lyme Disease Vaccine Candidate Shows High Efficacy in Phase 3 VALOR Trial

Pfizer and Valneva Announce Lyme Disease Vaccine Candidate Demonstrates Strong Efficacy in Phase 3 VALOR Trial Pfizer Inc. and Valneva SE announced topline results from the Phase 3 VALOR “Vaccine Against Lyme for Outdoor Recreationists” clinical trial (NCT05477524) of its…

Read MorePfizer and Valneva Report Promising Results as Lyme Disease Vaccine Candidate Shows High Efficacy in Phase 3 VALOR Trial
NuScale

NuScale Power and Ebara Elliott Energy partner to showcase advanced nuclear power for petrochemical plants.

NuScale Power and Ebara Elliott Energy Announce a Strategic Partnership to Showcase Use of Advanced Nuclear Technology to Power Petrochemical Plants NuScale Power Corporation the industry-leading provider of proprietary and innovative advanced small modular reactor (SMR) nuclear technology, and Ebara…

Read MoreNuScale Power and Ebara Elliott Energy partner to showcase advanced nuclear power for petrochemical plants.
ClearNote

ClearNote Health names Jeffrey Venstrom, MD, as CMO to advance early cancer test adoption.

ClearNote Health Appoints Jeffrey Venstrom, MD, as Chief Medical Officer and Expands Leadership Team to Drive Clinical Adoption of Early Cancer Detection Tests ClearNote Health, a company focused on improving early detection for some of the deadliest cancers, today announced…

Read MoreClearNote Health names Jeffrey Venstrom, MD, as CMO to advance early cancer test adoption.
Coya Therapeutics

Coya Therapeutics reports study linking T-cell dysfunction and inflammation in frontotemporal dementia, supporting COYA 302.

Coya Therapeutics Announces Publication Demonstrating Regulatory T-Cell Dysfunction and Systemic Inflammation in Frontotemporal Dementia, Supporting Mechanistic Rationale for COYA 302 Immune-Restoring Therapy Coya Therapeutics, Inc. a clinical-stage biotechnology company developing biologics intended to enhance Treg function, announces the publication of a…

Read MoreCoya Therapeutics reports study linking T-cell dysfunction and inflammation in frontotemporal dementia, supporting COYA 302.
PhaseWell

PhaseWell Research acquires Chase Medical Research to expand clinical trial capabilities in Connecticut.

PhaseWell Research Acquires Chase Medical Research to Expand Clinical Trial Capabilities in Connecticut PhaseWell Research a multisite clinical research company, today announced the strategic acquisition of Chase Medical Research (“CMR”). Under the leadership of founder, key opinion leader, and lead…

Read MorePhaseWell Research acquires Chase Medical Research to expand clinical trial capabilities in Connecticut.
Drug Farm

iECURE selected for the FDA CMC pilot program to support ECUR-506 manufacturing ahead of BLA submission.

iECURE Selected for U.S. FDA Chemistry, Manufacturing, and Controls Development and Readiness Pilot Program to Support Manufacturing Readiness of ECUR-506 Ahead of Planned BLA Submission iECURE, Inc., a clinical-stage genome editing company developing variant-agnostic in vivo targeted gene insertion therapies for the treatment…

Read MoreiECURE selected for the FDA CMC pilot program to support ECUR-506 manufacturing ahead of BLA submission.
GCE®

GCE® launched Gascontrol.com to showcase its complete gas control portfolio for specialty, medical, and industrial uses.

GCE® Launches Gascontrol.com Website Showcasing Its Complete Gas Control Portfolio for Speciality, Medical, and Industrial Applications GCE®, a global market leader for gas control equipment, has launched a new website designed to better serve customers across its GCE Specialty, GCE…

Read MoreGCE® launched Gascontrol.com to showcase its complete gas control portfolio for specialty, medical, and industrial uses.